In this role, he will be responsible for leading corporate financing, financial operations, treasury, investor relations, corporate communications and corporate strategy.
Previously, Chan served as Viela's vice president, head of finance and corporate strategy.
Chan has more than 15 years of finance experience. Prior to joining Viela in 2018, he served as director of Investor Relations for AstraZeneca, North America.
Previously, Chan held various roles of increasing responsibility at Genentech-Roche, including in BioOncology Commercial Finance, R and D Finance, and Mergers and acquisitions.
Chan is the recipient of Executive Certifications from Stanford University, University of California, and University of Pennsylvania (Wharton) and earned his BSc, MSc and MBA (Rotman School of Management) from the University Toronto.
Viela Bio, headquartered in Gaithersburg, Maryland, is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause of disease.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial